Symvess

Symvess is a preclinical-stage biotechnology company specializing in vascular-targeted therapeutics for inflammatory and thrombotic disorders. The company's core technology, licensed from the University of Pennsylvania, enables the precise delivery of therapeutic agents to the vascular endothelium using targeted nanocarriers and fusion proteins. Their primary focus is on treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) by anchoring drugs to endothelial markers such as PECAM-1. This targeted approach is designed to maximize local therapeutic effects while minimizing systemic side effects. Symvess is currently advancing a pipeline of candidates aimed at critical care and vascular medicine.